Christina Boull
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Boull has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Rachit Gupta
University of Minnesota Medical School Minneapolis MN USA
2 shared publications - Sheilagh Maguiness
Department of Dermatology University of Minnesota Minneapolis Minnesota USA
2 shared publications A. Yasmine Kirkorian
1 shared publication- Alexander Y. Maslov
Department of Genetics, Albert Einstein College of Medicine, Bronx, USA
1 shared publication Anna Cristina Garza-Mayers
1 shared publication- Ashley J. Housten
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, USA
1 shared publication
Latest Publications
- 3 April 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1729-1732.e1
Building consensus in pediatric dermatology research
- 3 April 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1729-1732.e1
Building consensus in pediatric dermatology research
- Open Access
- 20 February 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100209
High cancer-associated mutational burden in normal blood of xeroderma pigmentosum group C, but not groups A, D, or F
- 20 February 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100209
Open AccessHigh cancer-associated mutational burden in normal blood of xeroderma pigmentosum group C, but not groups A, D, or F
- 20 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2352-2361
Basal cell carcinoma risk prediction in survivors of childhood cancer
Background: Survivors of childhood cancer face excess risk of developing basal cell carcinoma. Age-specific basal cell carcinoma risk prediction models for survivors may support targeted screening recommendations. Methods: We developed models predicting basal cell carcinoma risk by ages 40 and 50 years featuring detailed cancer treatment predictors, utilizing statistical and machine-learning algorithms and data from 23 166 five-year survivors in the Childhood Cancer Survivor Study, a multi-institutional retrospective cohort study. Selected models were externally validated in 5314 survivors in the St Jude Lifetime Cohort. Model discrimination and precision were evaluated using the area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) and benchmarked against the current Children’s Oncology Group Long-Term Follow-Up Guidelines (COG LTFU, v6.0) for skin cancer screening. Results: By ages 40 and 50 years, basal cell carcinoma cumulative incidence was 5% and 15% in the Childhood Cancer Survivor Study and 7% and 21% in the St Jude Lifetime Cohort, respectively. The XGBoost algorithm-based models with treatment dose-specific predictors performed best, showing good external discrimination (age 40 years: AUROC = 0.75; age 50 years: AUROC = 0.76) and precision (age 40 years: AUPRC = 0.20; age 50 years: AUPRC = 0.52), outperforming COG LTFU Guideline-directed risk stratification (age 40 years: AUROC = 0.65; age 50 years: AUROC = 0.62; age 40 years: AUPRC = 0.09; age 50 years: AUPRC = 0.26; P < .01). These novel models reclassified 37% of survivors with COG-recommended skin cancer screening as low risk by age 40 years and 29% of survivors without COG-recommended screening as moderate or high risk by age 50 years, suggesting these recommendations overestimate risk in younger survivors and miss relevant predictors (eg, attained age, chemotherapy). Conclusions: In this study, we present validated basal cell carcinoma risk prediction models for childhood cancer survivors that outperform current practice guidelines. The associated online risk calculator can inform risk- and age-based screening recommendations.
- 20 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2352-2361
Basal cell carcinoma risk prediction in survivors of childhood cancer
Background: Survivors of childhood cancer face excess risk of developing basal cell carcinoma. Age-specific basal cell carcinoma risk prediction models for survivors may support targeted screening recommendations. Methods: We developed models predicting basal cell carcinoma risk by ages 40 and 50 years featuring detailed cancer treatment predictors, utilizing statistical and machine-learning algorithms and data from 23 166 five-year survivors in the Childhood Cancer Survivor Study, a multi-institutional retrospective cohort study. Selected models were externally validated in 5314 survivors in the St Jude Lifetime Cohort. Model discrimination and precision were evaluated using the area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) and benchmarked against the current Children’s Oncology Group Long-Term Follow-Up Guidelines (COG LTFU, v6.0) for skin cancer screening. Results: By ages 40 and 50 years, basal cell carcinoma cumulative incidence was 5% and 15% in the Childhood Cancer Survivor Study and 7% and 21% in the St Jude Lifetime Cohort, respectively. The XGBoost algorithm-based models with treatment dose-specific predictors performed best, showing good external discrimination (age 40 years: AUROC = 0.75; age 50 years: AUROC = 0.76) and precision (age 40 years: AUPRC = 0.20; age 50 years: AUPRC = 0.52), outperforming COG LTFU Guideline-directed risk stratification (age 40 years: AUROC = 0.65; age 50 years: AUROC = 0.62; age 40 years: AUPRC = 0.09; age 50 years: AUPRC = 0.26; P < .01). These novel models reclassified 37% of survivors with COG-recommended skin cancer screening as low risk by age 40 years and 29% of survivors without COG-recommended screening as moderate or high risk by age 50 years, suggesting these recommendations overestimate risk in younger survivors and miss relevant predictors (eg, attained age, chemotherapy). Conclusions: In this study, we present validated basal cell carcinoma risk prediction models for childhood cancer survivors that outperform current practice guidelines. The associated online risk calculator can inform risk- and age-based screening recommendations.
- Open Access
- 23 February 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 897-899
Use of dupilumab for atopic dermatitis in young transplant patients—A case series of 3 patients
Patients who undergo solid organ transplantation are at an increased risk of developing atopic dermatitis, potentially due to long-term use of calcineurin inhibitors which results in a shift towards the Th2 immune response. The effectiveness and safety of dupilumab for atopic dermatitis in posttransplant patients is not established. Previous reports of dupilumab use in posttransplant patients have been in adult patients. In this series, we report three young posttransplant patients treated successfully with dupilumab.
- 23 February 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 897-899
Open AccessUse of dupilumab for atopic dermatitis in young transplant patients—A case series of 3 patients
Patients who undergo solid organ transplantation are at an increased risk of developing atopic dermatitis, potentially due to long-term use of calcineurin inhibitors which results in a shift towards the Th2 immune response. The effectiveness and safety of dupilumab for atopic dermatitis in posttransplant patients is not established. Previous reports of dupilumab use in posttransplant patients have been in adult patients. In this series, we report three young posttransplant patients treated successfully with dupilumab.
- 15 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2424-2434
Interrogation of RDEB Epidermal Allografts after BMT Reveals Coexpression of Collagen VII and Keratin 15 with Proinflammatory Immune Cells and Fibroblasts
- 15 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2424-2434
Interrogation of RDEB Epidermal Allografts after BMT Reveals Coexpression of Collagen VII and Keratin 15 with Proinflammatory Immune Cells and Fibroblasts
- Open Access
- 1 March 2022
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 35 (2) , 435-442
Diagnosis and Management of Plantar Dermatoses
Plantar dermatoses (PD) are common, occurring either spontaneously on healthy skin or developing secondarily from previously established foot disease. PD share similar symptoms and morphology, making them challenging to differentiate. A few of the most frequently encountered PD include tinea pedis, psoriasis, contact dermatitis, dyshidrotic dermatitis (or recurrent vesicular palmoplantar dermatitis), and juvenile plantar dermatosis. This review offers practical advice for diagnosing and treating the most common PD in the primary care office.
- 1 March 2022
- Published by American Board of Family Medicine (ABFM) in The Journal of the American Board of Family Medicine
- Vol. 35 (2) , 435-442
Open AccessDiagnosis and Management of Plantar Dermatoses
Plantar dermatoses (PD) are common, occurring either spontaneously on healthy skin or developing secondarily from previously established foot disease. PD share similar symptoms and morphology, making them challenging to differentiate. A few of the most frequently encountered PD include tinea pedis, psoriasis, contact dermatitis, dyshidrotic dermatitis (or recurrent vesicular palmoplantar dermatitis), and juvenile plantar dermatosis. This review offers practical advice for diagnosing and treating the most common PD in the primary care office.
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (3) , AB91
26229 Use of dupilumab for atopic dermatitis in young post-transplant patients: A case series of 2 patients
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 85 (3) , AB91
26229 Use of dupilumab for atopic dermatitis in young post-transplant patients: A case series of 2 patients
- 11 July 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1191-1197
THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database
Background/Objective: Relative to adults, rates of melanoma are lower in children. Due to its rarity, it is difficult to assess the incidence, trends, and outcomes of this malignancy. Much of our understanding comes from single institution or regional cancer registries which may not be large enough to detect subtleties in the burden of pediatric melanoma.Methods: Data from the 2004 to 2016 National Cancer Database were analyzed; this database captures approximately 70% of all cancer diagnoses in the United States.Results: Our analysis consisted of 1903 cases. A majority were White (89.8%), the mean age was 12.4 years, and the ratio of females: males was 1.2:1.0. The most common anatomic location was the trunk (31.1%). Between 2004 and 2016, a decreasing trend in the number of new melanoma cases was observed. Comparing histologic subtype by age, there was an increased percentage of nodular and epithelioid and spindle cell tumors in the pre‐teen children and a greater percentage of superficial spreading tumors in teenagers. Overall, a majority of cases were stage 0 or I (56.9%), with relatively few stage IV cases (2.0%). A 5‐year all‐cause survival of greater than 90% was observed for stage I‐III tumors, with stage IV tumors having a 5‐year all‐cause survival of 34.4%.Conclusion: Comparable to previous studies, pediatric melanoma occurred most often in Whites, females, and adolescents. However, we detected a decreasing trend in new cases, noted differences between histologic subtype and age, and observed a 5‐year all‐cause survival rate of greater than 90% for stage I‐III tumors.
- 11 July 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1191-1197
THE demographics and trends in pediatric melanoma in the United States: An analysis of the National Cancer Database
Background/Objective: Relative to adults, rates of melanoma are lower in children. Due to its rarity, it is difficult to assess the incidence, trends, and outcomes of this malignancy. Much of our understanding comes from single institution or regional cancer registries which may not be large enough to detect subtleties in the burden of pediatric melanoma.Methods: Data from the 2004 to 2016 National Cancer Database were analyzed; this database captures approximately 70% of all cancer diagnoses in the United States.Results: Our analysis consisted of 1903 cases. A majority were White (89.8%), the mean age was 12.4 years, and the ratio of females: males was 1.2:1.0. The most common anatomic location was the trunk (31.1%). Between 2004 and 2016, a decreasing trend in the number of new melanoma cases was observed. Comparing histologic subtype by age, there was an increased percentage of nodular and epithelioid and spindle cell tumors in the pre‐teen children and a greater percentage of superficial spreading tumors in teenagers. Overall, a majority of cases were stage 0 or I (56.9%), with relatively few stage IV cases (2.0%). A 5‐year all‐cause survival of greater than 90% was observed for stage I‐III tumors, with stage IV tumors having a 5‐year all‐cause survival of 34.4%.Conclusion: Comparable to previous studies, pediatric melanoma occurred most often in Whites, females, and adolescents. However, we detected a decreasing trend in new cases, noted differences between histologic subtype and age, and observed a 5‐year all‐cause survival rate of greater than 90% for stage I‐III tumors.